2025-08-29 04:01:26
Latest Post
Himadri Speciality Chemical Ltd Secures ISCC PLUS Certification
HCLSoftware delivers Digital Independence with AI-Powered Sovereign Collaboration Solutions for Business-Critical Infrastructure
Dr. Agarwal's Health Care Limited and Dr. Agarwal's Eye Hospital Limited announce Merger
SAMHI signs agreement to Lease for ~260-room Mid-Scale Hotel in Hyderabad's Financial District
Rail Vikas Nigam Ltd signs JV agreement with Texmaco Rail & Engineering Ltd
Stock Report
Bal Pharma Q3FY22 consolidated net profit reduces to Rs. 47.43 lakhs
Posted On : 2022-02-11 09:07:27( TIMEZONE : IST )
Bal Pharma Limited has reported Consolidated financial results for the period ended December 31, 2021.
Financial Results (Q3 FY2022) - QoQ Comparison
The company has reported total income of Rs. 69.9191 crores during the period ended December 31, 2021 as compared to Rs. 67.7312 crores during the period ended September 30, 2021.
The company has posted net profit / (loss) of Rs. 0.4743 crores for the period ended December 31, 2021 as against net profit / (loss) of Rs. 1.3941 crores for the period ended September 30, 2021.
The company has reported EPS of Rs. 0.32 for the period ended December 31, 2021 as compared to Rs. 0.94 for the period ended September 30, 2021.
| Financials | Q3 FY2022 | Q2 FY2022 | % Change |
| Total Income | ₹69.9191 crs | ₹67.7312 crs |  3.23% |
| Net Profit | ₹0.4743 crs | ₹1.3941 crs |  -65.98% |
| EPS | ₹0.32 | ₹0.94 | -65.96% |
Financial Results (Q3 FY2022) - YoY Comparison
The company has reported total income of Rs.69.9191 crores during the period ended December 31, 2021 as compared to Rs.63.2194 crores during the period ended December 31, 2020.
The company has posted net profit / (loss) of Rs.0.4743 crores for the period ended December 31, 2021 as against net profit / (loss) of Rs.0.4011 crores for the period ended December 31, 2020.
The company has reported EPS of Rs.0.32 for the period ended December 31, 2021 as compared to Rs.0.28 for the period ended December 31, 2020.
| Financials | Q3 FY2022 | Q3 FY2021 | % Change |
| Total Income | ₹69.9191 crs | ₹63.2194 crs | 10.60% |
| Net Profit | ₹0.4743 crs | ₹0.4011 crs | 18.25% |
| EPS | ₹0.32 | ₹0.28 | 14.29% |
Financial Results (9 Months Ended FY2022) - YoY Comparison
The company has reported total income of Rs.208.6135 crores during the 9 Months period ended December 31, 2021 as compared to Rs.180.1292 crores during the 9 Months period ended December 31, 2020.
The company has posted net profit / (loss) of Rs.3.5175 crores for the 9 Months period ended December 31, 2021 as against net profit / (loss) of Rs.1.1814 crores for the 9 Months period ended December 31, 2020.
The company has reported EPS of Rs.2.37 for the 9 Months period ended December 31, 2021 as compared to Rs.0.83 for the 9 Months period ended December 31, 2020.
| Financials | 9 Months Ended FY2022 | 9 Months Ended FY2021 | % Change |
| Total Income | ₹208.6135 crs | ₹180.1292 crs | 15.81% |
| Net Profit | ₹3.5175 crs | ₹1.1814 crs | 197.74% |
| EPS | ₹2.37 | ₹0.83 | 185.54% |
Shares of Bal Pharma Limited was last trading in BSE at Rs. 122.40 as compared to the previous close of Rs. 123.60. The total number of shares traded during the day was 10003 in over 453 trades.
The stock hit an intraday high of Rs. 126.00 and intraday low of 120.55. The net turnover during the day was Rs. 1236602.00.
